KRON 주가, 뉴스, 차트, 주식 조사, 프로필.

 (KRON) 주식 시세 및 뉴스 요약

KRONOS BIO INC

Kronos Bio

Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.

Deal Dispatch

Commodities

Exclusives

Interview

AMCR

BERY

BMWYY

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

GOOG

GOOGL

KRON

MEIP

NISTF

PARA

SAVE

SBUX

SHEL

TSX:SGO

ULCC

VWAGY

새로이 등장한 블록 스타벅스(NASDAQ:SBUX)가 중국 사업의 일부 지분을 매각하려고 한다. 최근 1분기 중국 내 동일 매장 매출이 14% 감소하면서, 시애틀에 본사를 둔 이 커피 소매업체는 치열한 경제적 및 경쟁적 압박에 적응하기 위한 파트너십을 모색하고 있다.

딜 디스패치: 스타벅스 중국 사업 매각 고려, 노스볼트 파산, 다윈 파이낸셜이 광업에 대해 논의

AAUKF

APTV

ATSG

FFIV

PARIS:SGO

ROIC

SLGWF

SLNG

TRIP

새로 등장한 블록 에볼런트 헬스(NYSE:EVH)가 매물로 나온 것으로 알려졌다. 버지니아 주 알링턴에 본사를 둔 이 소프트웨어 회사는 인수 문의를 받은 후 경매 프로세스를 시작했다. 잠재적인 구혼자 중에는 TPG(NASDAQ:TPG), 클레이톤, 듀블리에 &amp; 라이스(Clayton, Dubilier &amp; Rice), KKR &amp; 컴퍼니(NYSE:KKR)가 있다. 로이터는 건강 보험사 엘레반스 헬스(NYSE:ELV)가 한 사모 펀드 파트너와 협력하여 거래를 추진할 수 있다고 보고했다.

딜 디스패치: 쉘, 유니레버 외에도 매각 뉴스; 어니언이 알렉스 존스의 인포워스 인수 등

Kronos Bio Inc

Krones AG

KRONOS ADVANCED TECHS INC by Kronos Advanced Technologies, Inc.

Kronos Advanced Technologies Inc

Kronos Worldwide Inc

Wells Fargo analyst Ken Gawrelski maintains Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Equal-Weight and lowers the price target from $5248 to $4567.

News

Price Target

Analyst Ratings

BKNG

Wells Fargo Maintains Equal-Weight on Booking Holdings, Lowers Price Target to $4567

UBS analyst Joshua Spector maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Neutral and lowers the price target from $60 to $46.

UBS Maintains Neutral on Celanese, Lowers Price Target to $46

Following the Trump Administration announcing <a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">wide-ranging tariffs</a> on all imported products, with rates starting at 10% and going higher depending on the country, Needham published last Thursday, Friday, and Monday&#8217;s initial reactions to their coverage areas on who has the most exposure.
Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) stock <a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44651515/apple-analyst-holds-the-line-after-300-billion-rout-what-could-turn-stock-around" rel="noreferrer noopener">fell nearly 10% Thursday</a>, losing about $300 billion of market cap, owing to new tariffs. However, unless Apple gets an exemption, analyst Laura Martin calculated that Apple&#8217;s adjusted EPS will fall by over $2, down 28% from the analyst&#8217;s current fiscal 2025 EPS estimate of $7.32.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/global/25/04/44645946/microsoft-halts-data-center-expansions-due-to-semiconductor-tariff-concerns-ai-overcapacity-fears" rel="noreferrer noopener">Microsoft Halts Data Center Expansions Due To Semiconductor Tariff Concerns, AI Overcapacity Fears</a>
By implication, Wall Street is betting there is a 30% chance Apple will get an exemption because Trump gave it an exemption in 2018.
The company committed to spending $500 billion in the U.S. over 4 years, creating 20,000 new jobs, and it is the most iconic U.S. brand in the world.
EPS down 28% is not the worst case. China retaliates against the U.S. by banning all or some Apple product sales in China, which were 17% of Apple&#8217;s total sales in fiscal 2024, which can pose a bigger threat.
Martin noted that DoubleVerify Holdings, Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DV#NYSE">DV</a>) business model is based on a fixed fee, not a revenue share of ad spending. The analyst noted that 100% of DoubleVerify&#8217;s revenue is virtual.
As per Martin, 30% of the company revenue is from outside the U.S., which is yet to be impacted. DoubleVerify verifies advertising in both Walled Gardens and the Open Internet, so if advertising happens anywhere, DoubleVerify should earn its fees.
DoubleVerify is well diversified across verticals, without significant exposure to industrials, autos, or durables, which are the most at risk from tariffs and fundamental growth drivers like new customers from moat, more up-sells of additional products to existing customers, incremental traction on DoubleVerify&#8217;s Meta pre-bid product, and new business wins could offset tariff-related weakness.&nbsp;&nbsp;
The impact of new tariffs on Viant Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSP#NASDAQ">DSP</a>) is 100% advantageous (i.e., virtual), with no hard goods. Viant Technology is missing the three most tariff-exposed ad categories: industrials, durables, and national autos.
Viant Technology&#8217;s largest ad categories are U.S. healthcare, U.S. universities, education, and travel/hospitality. Together, local autos plus CPG were less than 20% of total ad revenue in 2024, Martin estimated. So far, prior tariffs have only negatively impacted ad spending on avocados from Mexico.
Price Action: AAPL stock is trading lower by 4.89% to $179.26 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/asia/25/04/44668137/nio-power-in-deal-talks-with-tesla-battery-supplier-catl" target="_blank" rel="noreferrer noopener">Nio Power In Deal Talks With Tesla Battery Supplier CATL</a></li>
</ul>
Image via Shutterstock

Analyst Color

Movers

Tech

Trading Ideas

AAPL

Analyst Forecasts Tariffs Impact On Apple's Profit And Highlights 2 Software Stocks That Are Safeguards

UBS analyst Joshua Spector maintains Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) with a Buy and lowers the price target from $123 to $115.

UBS Maintains Buy on Eastman Chemical, Lowers Price Target to $115

Wisconsin voters just sent a message that money doesn't buy everything.
In what became the most expensive judicial election in U.S. history, liberal judge Susan Crawford defeated conservative Brad Schimel to retain the Wisconsin Supreme Court&#8217;s 4-3 liberal majority. The race drew national attention not only for its implications but for the amount of money poured into it, and who was behind it.
<h2 class="wp-block-heading">Sanders Celebrates Grassroots Victory</h2>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Congratulations Wisconsin on electing Susan Crawford. As a result of your strong grassroots organizing, you have defeated the wealthiest person on earth. You have set an example for the rest of the country. We can do it. <a href="https://t.co/hpbsV7tFzi">https://t.co/hpbsV7tFzi</a>
&mdash; Bernie Sanders (@BernieSanders) <a href="https://twitter.com/BernieSanders/status/1907261465909686750?ref_src=twsrc%5Etfw">April 2, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">With Shares Starting at Just $1.52, This Could be Your Chance to Invest in the Future of Healthcare.</a></li>
</ul>
Sen. Bernie Sanders (I-VT) praised voters on X, formerly Twitter, <a href="https://x.com/BernieSanders/status/1907261465909686750">writing</a>: &#8220;Congratulations Wisconsin on electing Susan Crawford. As a result of your strong grassroots organizing, you have defeated the wealthiest person on earth. You have set an example for the rest of the country. We can do it.&#8221;
That &#8220;wealthiest person&#8221; is Elon Musk, who spent around $25 million backing Crawford's opponent. In all, more than $100 million was spent in the race, which included high-dollar donations on both sides, though Musk outspent everyone.
<h2 class="wp-block-heading">What's at Stake</h2>
With Wisconsin being a critical swing state, the court is expected to play a key role in decisions about congressional redistricting ahead of the 2026 midterms and the 2028 presidential election. Democrats currently hold four seats on the court, and Crawford&#8217;s win keeps that majority intact.
Trending: <a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a>
As Musk himself put it in a Fox News <a href="https://www.youtube.com/watch?v=LQLZTIIW5ug&amp;t=625s">interview</a> before the election, &#8220;Losing this judge race has a good chance of causing Republicans to lose control of the House. [In that case] there will be nonstop impeachment hearings and subpoenas.
<h2 class="wp-block-heading">&#8216;Our Courts Are Not for Sale&#8217;</h2>
&#8220;Wisconsin stood up and said loudly that justice does not have a price. Our courts are not for sale,&#8221; Crawford said in her victory speech.
Crawford, a Dane County judge and former lawyer for Planned Parenthood, campaigned in support of abortion rights and opposed a recent voter ID constitutional amendment. That amendment passed, making it harder to change existing ID laws in the future.
Despite being outspent, Crawford&#8217;s campaign benefited from strong Democratic turnout and support from major donors like George Soros, Illinois Gov. J.B. Pritzker and <a href="https://www.benzinga.com/25/03/44369839/linkedin-co-founder-reid-hoffman-tells-stephen-colbert-why-elon-musk-running-the-doge-department-like-a-business-should-worry-us-all-government-and-companies-are-not-the-same">LinkedIn co-founder Reid Hoffman</a>.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.
<h2 class="wp-block-heading">Musk&#8217;s Role in the Race</h2>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I expected to lose, but there is value to losing a piece for a positional gain
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1907330613348073750?ref_src=twsrc%5Etfw">April 2, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Musk was more than just a donor. His political action committee offered cash incentives to voters who supported Schimel, including $100 payouts and even <a href="https://www.benzinga.com/news/global/25/03/44555540/elon-musk-sparks-legal-showdown-with-1-million-voter-payouts-in-wisconsin-defying-court-battle">two $1 million checks handed out at a rally</a>. His involvement sparked criticism and became a focal point in Democratic messaging.
During a rally, Musk said the judicial race was really about &#8220;control of the U.S. House of Representatives,&#8221; alluding to the court&#8217;s potential role in shaping congressional districts. Republicans currently hold six of Wisconsin&#8217;s eight seats in the House.
Still, Musk seemed unfazed after the loss, <a href="https://x.com/elonmusk/status/1907330613348073750">writing</a> on X: &#8220;I expected to lose, but there is value to losing a piece for a positional gain.&#8221;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/startengine-own">The $1.3 billion startup investment boom: How this company's explosive growth is opening doors for everyday investors with a new $500 minimum</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

'You Have Defeated The Wealthiest Person On Earth,' Says Bernie Sanders As He Applauds Wisconsin's Choice Of Susan Crawford

UBS analyst Josh Silverstein maintains Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) with a Neutral and lowers the price target from $41 to $36.

UBS Maintains Neutral on Range Resources, Lowers Price Target to $36

Global

Trump Says 'Not Looking At That' When Asked About Tariff Pause; Trump Says Japan Is Going To Have To Open Up Its Country

UBS analyst Joshua Spector maintains Sherwin-Williams (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) with a Buy and lowers the price target from $430 to $400.

UBS Maintains Buy on Sherwin-Williams, Lowers Price Target to $400

UBS analyst Josh Silverstein maintains Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) with a Buy and lowers the price target from $37 to $33.

CTRA

UBS Maintains Buy on Coterra Energy, Lowers Price Target to $33

UBS analyst Joshua Spector maintains Cabot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBT#NYSE">CBT</a>) with a Neutral and lowers the price target from $93 to $83.

UBS Maintains Neutral on Cabot, Lowers Price Target to $83

Macro Economic Events

Economics

Trump Says We're Having Direct Talks With Iran, Says Doing A Deal Would Be Preferable

UBS analyst Joshua Spector maintains Methanex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEOH#NASDAQ">MEOH</a>) with a Buy and lowers the price target from $66 to $53.

MEOH

UBS Maintains Buy on Methanex, Lowers Price Target to $53

<a href="https://asia.nikkei.com/Politics/International-relations/Bessent-to-lead-U.S.-tariff-talks-with-Japan-with-yen-on-agenda" title="https://asia.nikkei.com/Politics/International-relations/Bessent-to-lead-U.S.-tariff-talks-with-Japan-with-yen-on-agenda">https://asia.nikkei.com/Politics/International-relations/Bessent-to-lead-U.S.-tariff-talks-with-Japan-with-yen-on-agenda</a>

Forex

Markets

Nikkei: 'Bessent to lead U.S. tariff talks with Japan, with yen on agenda'

UBS analyst Josh Silverstein maintains Exxon Mobil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) with a Buy and lowers the price target from $146 to $135.

UBS Maintains Buy on Exxon Mobil, Lowers Price Target to $135

UBS analyst Joshua Spector maintains Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) with a Buy and lowers the price target from $144 to $127.

UBS Maintains Buy on Westlake, Lowers Price Target to $127

President Donald Trump's Liberation Day is living up to its name, though perhaps not in the way the administration envisioned. Thanks to last week's sweeping wave of tariffs, technical analysts have sounded the alarm about the potential for a <a href="https://www.benzinga.com/general/market-summary/25/04/44662164/us-stock-futures-slump-following-massive-tariff-induced-selloff-experts-warn-of-a-brewing-great-depression-like-pattern">steep downturn reminiscent of the Great Depression</a>. Adding to the anxieties is that precious few companies have been spared volatility, not even tech juggernaut NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
While the bulls are mounting a comeback effort on Monday, over the past five sessions, NVDA stock lost roughly 11%. Since the start of the year, equity has slipped 28%, reflecting a dramatic turn of events tied to the post-pandemic recovery. Throughout 2023 and especially 2024, Nvidia saw its valuation skyrocket thanks to demand for its graphics processors, which have undergirded the artificial intelligence revolution.
Unfortunately for the optimists, a combination of competitive pressures, new rivals in the AI ecosystem and unfavorable (at least for now) political frameworks have created a headwind for NVDA stock. As such, market makers are pricing in negative outcomes for NVDA options, which makes perfect sense. If analysts are mentioning the Great Depression, it's safe to say that sentiment is poor.
However, the pessimism has gotten so rough that the risk profile in certain option spreads has become inverted, so to speak. This backdrop is creating an enticing proposition for clever contrarians.
<h2 class="wp-block-heading">How To Lose And Still Win With NVDA Stock</h2>
For the typical bull call spread strategy — especially one underlying a strong business enterprise like Nvidia — the target equity must rise above a breakeven threshold to be profitable. This makes intuitive sense because the trader is paying a net debit to hopefully realize a specific outcome.
On the other hand, sellers of call spreads are essentially betting against this outcome materializing. These folks start their position from a cash influx because they receive a credit (the debit the call buyer is paying). As such, call spread sellers aren't necessarily hoping that the security falls in value. Rather, just moving sideways is often good enough for the seller to keep the entire premium received.
What makes the present circumstance unique is that the fear of volatility is so intense that relatively high-payout bull call spreads don't require NVDA stock to rise. Instead, it just can't fall too much, which is, frankly, a wildly compelling deal.
Take, for example, the 92/93 bull call spread for the options chain expiring this coming Friday. This transaction involves buying the $92 call (at a time-of-writing ask of $690) and simultaneously selling the $93 call (at a bid of $620). The proceeds from the short call partially offset the debit paid for the long call, resulting in a net cash outlay of $70.
Should NVDA stock stay at or above the short strike price at expiration, the maximum reward comes from the difference between the strike prices (multiplied by 100 shares) minus the cash outlay or $30. That's a payout of nearly 43% — and NVDA doesn't have to rise! Currently, the market price is above the short strike price, so NVDA can even decline and still qualify for the full reward.
Of course, the market fluctuates constantly, so exact parameters may change. But currently, because of the tariff turmoil, the risk profile in certain call spreads is inverted. Rather than a traditional debit structure, the aforementioned call spread acts almost like a credit spread—but to the benefit of the debit buyer.
<h2 class="wp-block-heading">The Compelling Math Behind the Risk Inversion</h2>
Based on pricing data since January 2019, the probability that any given week will be profitable is 56.13%. This is calculated by taking the number of up weeks divided by the total number of weeks in the dataset. As a baseline, then, the trader enjoys a house advantage when buying the aforementioned 92/93 bull spread expiring this week.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07140322/NVDA-stock-probabilities-04072025-1024x576.jpg" alt="" class="wp-image-860524" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07140322/NVDA-stock-probabilities-04072025-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07140322/NVDA-stock-probabilities-04072025-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07140322/NVDA-stock-probabilities-04072025-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07140322/NVDA-stock-probabilities-04072025.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
However, the question isn't whether NVDA stock will rise this week or not. Rather, it's the odds that NVDA will not drop below $93, the short strike price of the aforementioned call spread. Mathematically, traders spotted a 2% safety margin relative to the time-of-writing price of around $95. Therefore, the odds are focused on whether NVDA will at least do better than lose 2% this week.
On any given week, the chance that Nvidia stock will perform better than a 2% loss is nearly 72%.
Granted, this isn't a pure arbitrage situation. There's still risk involved and no guarantee that this call spread will be profitable. If another unprecedented event materializes, then NVDA stock may collapse beyond the magnitude provided by the safety margin.
Still, the bottom line is that the house is giving gamblers both a robust payout and some wiggle room. Such combinations don't come around too often.
Photo: Shutterstock

Equities

Long Ideas

Options

NVDA

Options Corner: Trump 2.0 Trauma Sparks 'Risk Inverted' Nvidia Call Spreads

UBS analyst Joshua Spector maintains Olin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) with a Neutral and lowers the price target from $34 to $21.

UBS Maintains Neutral on Olin, Lowers Price Target to $21

Amneal Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>) revealed a new analysis of the pivotal <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">RISE-PD Phase 3 study</a> on Monday.
The data showed that patients who converted to Crexont from immediate release (IR) carbidopa/levodopa (CD/LD) experienced <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44664141/amneal-announces-new-data-from-phase-3-study-showing-significant-improvements-in-sleep-quality-wit" rel="noreferrer noopener">improved sleep quality</a>.
These improvements were measured by their Parkinson&#8217;s Disease Sleep Scale-2 (PDSS-2) total scores, showing a mean difference of -2.35 (p&lt;0.0001).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/44040038/generic-drugmaker-amneal-clocks-mixed-q4-earnings-plans-expansion-in-high-growth-areas-like-weight-loss-products-biosimilars" rel="noreferrer noopener">Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars</a>
Crexont, indicated for Parkinson&#8217;s disease (PD), is a novel CD/LD formulation that combines IR granules and extended-release pellets. This innovative design allows for rapid onset while leveraging a sustained-release polymer for slow LD release, potentially enabling longer LD absorption in the gut.
The new analysis showed that patients on Crexont, compared to IR CD/LD, also experienced statistically significant improvements across all PDSS-2 subdomains, including reduced disturbed sleep (-1.07, p&lt;0.0001), improved nighttime motor symptoms (‑0.62, p&lt;0.0059) and PD symptoms at night (-0.65, p&lt;0.0017).
A separate analysis of Hauser diary entries, a commonly used PD symptom tracking tool, from patients who completed the RISE-PD study will also be presented at AAN.
Treatment with CREXONT compared to IR CD/LD significantly increased the number of patients who reported waking up in an &#8220;On&#8221; state and patients who never recorded being in an &#8220;Off&#8221; state upon awakening.
Furthermore, the percentage of patients who never recorded &#8220;On&#8221; upon awakening decreased with Crexont vs. IR CD/LD.
Amneal has initiated a Phase 4 clinical trial, ELEVATE-PD, to evaluate the real-world efficacy and safety of CREXONT in patients with PD.
Price Action: AMRX stock is down 2.85% at $7.17 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44653345/bofa-analyst-forecasts-slower-growth-for-broker-stocks-as-market-volatility-increases" target="_blank" rel="noreferrer noopener">BofA Analyst Forecasts Slower Growth For Broker Stocks As Market Volatility Increases</a></li>
</ul>

Health Care

General

AMRX

Amneal's Combination Drug Shows Improved Sleep Quality In Parkinson's Disease Patients

UBS analyst Joshua Spector maintains Dow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) with a Neutral and lowers the price target from $41 to $29.

UBS Maintains Neutral on Dow, Lowers Price Target to $29

Treasury Secretary Scott Bessent To Lead U.S. Tariff Talks With Japan, With Yen On Agenda

Press Releases

Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer

Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy

Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma

Earnings

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

Management

Kronos Bio Announces CEO Transition and Reduction in Force

Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results

bluebird bio

Cibus

Cue Biopharma

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Fortress Biotech

Gain Therapeutics

Immix Biopharma

Inozyme Pharma

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

PMV Pharma

Repare Therapeutics

Skye Bioscience

Sutro Biopharma

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

Piper Sandler

HC Wainwright & Co.

Goldman Sachs

Berenberg

Kronos

Learn About Cryptocurrency

acf/sidebar-related-posts

Learn about this leading blockchain platform that supports decentralized applications and smart contracts.

What is Ethereum?

Earning interest on your Ethereum is a great way to grow your cryptocurrency holdings. Find out how to earn interest on your Ethereum in 4 easy steps.

How to Earn Interest on Ethereum

Discover the 10 best cryptocurrencies to invest in for January 2025. Stay ahead in the crypto market with our expert insights and analysis! Learn more now!

10 Best Cryptocurrencies to Invest In for April 2025

10 Best Cryptocurrencies to Invest in for January 2025

Discover the best altcoins to invest in for high potential returns. Our top altcoin picks include Ethereum, Solana, Ripple, Dogecoin, Toncoin.

Top 10 Best Altcoins • Benzinga Crypto

10 Best Altcoins in November 2024

Top Cryptocurrency News

acf/news-feed

개장가	-
종가	-
거래량 / 평균	- / -
일 범위	- - -
52주 범위	- - -
시가 총액	-
P/E 비율	-
배당 수익률	-
거래소
RSI	26
매도 수량	1.61%
커버링 기간	4.67

개장가	-
종가	-
거래량 / 평균	- / -
일 범위	- - -
52주 범위	- - -
시가 총액	-
P/E 비율	-
배당 수익률	-
거래소
RSI	26
매도 수량	1.61%
커버링 기간	4.67

Comments

예보

(KRON) 주식 시세 및 뉴스 요약

최근 뉴스

재무

분석가 추세

분석가 평가

비교

FAQ

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌

종목명

매출 변동
총 변동
EBITDA 변동
EBIT 변동
실적 변동